Suggestions

Du même auteur

Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study

Archive ouverte | Tilly, Hervé | CCSD

International audience

Résultats actualisés d’une l’étude de phase Ib/II chez des patients atteints de lymphome diffus à grandes cellules B (LDGCB) en rechute/réfractaire (R/R) traités par polatuzumab vedotin (Pola) plus bendamustine (B) et rituximab (R) ou obinutuzumab (G)

Archive ouverte | Jardin, Fabrice | CCSD

International audience

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

Archive ouverte | Sehn, Laurie H | CCSD

International audience. BACKGROUND: Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate disease control with rituximab-based treatment have few treatment options and a poor prognosis. We aimed t...

Chargement des enrichissements...